

1. **INTRODUCTION:** International Journal of Interdisciplinary Dentistry-IJoID (<http://www.ijoid.cl/>) is the continuation of the Clinical Journal of Periodontology, Implantology and Oral Rehabilitation, which has been published continuously since 2008. It is a peer-reviewed journal of Dentistry. It is currently the organ of scientific expression of the Scientific Societies of Periodontology, Oral Implantology, Prosthodontics, and Oral Rehabilitation, Pediatric Dentistry and Orthodontics of Chile, in addition to the Ibero-Pan American Federation of Periodontology and the Latin American Association of Oral Rehabilitation ((AILARO). It is published with three regular issues per year.

International Journal of Interdisciplinary Dentistry-IJoID publishes scientific and practical articles on Periodontics, Osseointegration, Implantology, Prosthodontics, Oral Rehabilitation, Pediatric Dentistry, Orthodontics, and directly related specialties. The Journal is included in SciELO, Redalyc, Latindex, and Sociedad Iberoamericana de Información Científica.

Authors could submit articles in Spanish and English. When the report is presented in Spanish, it must include title, abstract, and keywords in English; when it is in English, the author must attach a letter or certificate indicating the responsibility for reviewing the article in that language. If the manuscript is in English, it should **NOT** include an abstract, title, or Spanish keywords.

IJoID adheres to international publication standards that regulate the ethical aspects of publications and/or are nowadays guidelines for publication in most biomedical journals. Primarily, it adheres to the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" promoted and periodically updated by the International Committee of Medical Journal Editors ([ICMJE](#)) known as the "Vancouver Standards." We recommend that manuscripts submitted should be guided by the standards recommended by the international initiative known as [The EQUATOR Network](#) (Enhancing the QUALity and Transparency Of health Research). We recommend that you select and read what these standards stipulate before submitting your manuscript to us.

All manuscripts are subject to peer review by reviewers outside the Editorial Board of the Journal, which conducts a single-blind review of the articles.

2. **ETHICAL RESPONSIBILITIES:** IJoID adheres to the ethical guidelines for research and publication described below:

- 2.1. **Authorship and Acknowledgments:** all authors of a manuscript must agree to submit the document to the Journal.

IJoID adheres to the definition of authorship created by the International Committee of Medical Editors (ICMJE). According to ICMJE, the criteria for authorship must be based on 1) substantial contributions to

the conception and design or acquisition of data or analysis and interpretation of data, 2) drafting of the article or critical review of its important intellectual content, and 3) approval of the version to be published. Authors must comply with all conditions.

All authors and co-authors should be credited in submitting the manuscript (including their email address); those who do not qualify as authors should be mentioned in the acknowledgments.

Acknowledgments should specify the contributors to the article other than the credited authors.

- 2.2. **Ethical approvals:** Research involving human participants, human material, or human data must have been conducted by the [Declaration of Helsinki](#) and approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and reference number, if applicable, should appear in all manuscripts reporting such research. If a study has been exempted from requiring ethics approval, this should also be detailed in the document (including the ethics committee's name granted the exemption). Further information and supporting documentation should be made available to the Editor upon request. Manuscripts may be rejected if the Editor considers that the research has not been conducted within an appropriate ethical framework. In exceptional cases, the Editor may contact the Ethics Committee for further information.
- 2.3. **Consent to Participate:** When research involving humans, informed consent to participate in the study must be obtained (or from their parents or legal guardians in the case of those under 16 years of age), and a statement to that effect must be included in the manuscript. In the case of manuscripts reporting studies involving vulnerable groups (e.g., unconscious patients), where there is the possibility that the study may be conducted in an unconscious patient, a statement to that effect should be included in the manuscript.
- 2.4. **Sex and Gender in Research (SAGER):** We expect our authors to follow the "[Guidelines on Sex and Gender Equity in Research \(SAGER\)](#)" and to include sex and gender considerations when relevant. Authors should use the terms sex (biological attribute) and gender (shaped by social and cultural circumstances) to avoid confusing the two terms. Article titles and abstracts should indicate to which sex or sexes the study applies. Authors should also describe in the background whether sex and/or gender differences are to be expected; report how sex and/or gender have been taken into account in the study design; provide data disaggregated by sex and/or gender, where appropriate; and discuss the individual results. If an analysis by sex and/or gender has not been performed, the rationale should be stated in the Discussion. We suggest that authors consult the complete guidelines before submission.
- 2.5. **Animal research:** Experimental research involving animals must comply with institutional, national, or international standards and, if applicable, must have been approved by an appropriate ethics committee. [The Basel Declaration](#) outlines the fundamental principles to be followed when conducting animal research, and the International Council for Laboratory Animal Science (ICLAS) has also published [ethical guidelines](#). The minutes of approval by the appropriate committee should be included in the manuscript. If a study has

been granted an exemption from requiring ethics approval, this should also be detailed in the document (including the name of the ethics committee that granted the exemption and the reasons for the exemption). The Editor will consider animal welfare issues and reserves the right to reject a manuscript, mainly if the research includes protocols that do not conform to commonly accepted standards of animal research.

**2.6. Publication guidelines:** IJoID encourages complete and transparent reporting of dental research. Please refer to the checklist of minimum reporting standards when reporting your research. We request recommend that authors consult the minimum reporting guidelines for dental research found on the [EQUATOR](#) Network when preparing their manuscript and [FAIRsharing.org](#) for reporting checklists for biological and biomedical research, where applicable. Authors should follow these guidelines when writing their documents, and reviewers will be asked to refer to these checklists when evaluating such studies.

Lists exist for several study designs, including:

Randomized controlled trials ([CONSORT](#)) and clinical trial protocols ([SPIRIT](#)).

Evidence Synthesis (including: Systematic Reviews ([PRISMA](#)), Comprehensive Syntheses (Overviews or Umbrella, Mapping and Scoping Reviews among others) and their corresponding protocols ([PRISMA-P](#)))

Observational studies ([STROBE](#))

Clinical Cases ([CARE](#))

Qualitative research ([COREQ](#))

Diagnostic/prognostic studies ([STARD](#) and [TRIPOD](#))

Economic evaluations ([CHEERS](#))

Clinical Practice Guidelines ([AGREE](#) and [RIGHT](#))

Preclinical animal studies ([ARRIVE](#))

Publication guidelines for other study designs can be found in the [EQUATOR NETWORK](#).

**2.7 Statistical methods:** Authors should include complete information on the statistical methods and measures used in their research, including the justification for the statistical test's appropriateness (see [SAMPL](#) guidelines). Reviewers will be asked to check the statistical methods, and the manuscript may be sent for expert statistical review if deemed necessary.

**2.8. Synthesis of evidence:** This section publishes: systematic reviews that should be written following the PRISMA guideline, and the checklist should be included in Supplemental File for Review as submission material. Besides, the Systematic Review must have a registration number in one of the sites that register systematic review protocols ([PROSPERO](#), [OSFHOME](#)). Other synthesis formats including, mapping reviews, umbrella reviews, scoping reviews whose protocols must be enrolled in [PROSPERO](#), [OSFHOME](#). Mapping reviews adhere to the Global Evidence Mapping Initiative ([GEM](#)) methods incorporating the quality of supporting evidence. Umbrella reviews (overviews) must follow [PRIOR](#) standards and scoping reviews must follow [JBI](#) standards whose protocol must be registered with [PROSPERO](#).

- 2.9. **Structured Summaries of Evidence:** In this section structured summaries of evidence are published, such as CAT ([Critically Appraised Topics](#)), POEM (patient-oriented Evidence that Matters) and FRISBEE ([FRIendly Summary of the Body of Evidence using Epistemonikos](#)), among others.
- 2.10. **Clinical Trials:** Clinical trials should be reported using the CONSORT guidelines. The CONSORT checklist should also be included in the submission material in Supplemental File for Review. The clinical trial must also have a registration number in one of the clinical trial protocol registration sites associated with the WHO International Registration Platform (<http://www.who.int/ictrp/es>).
- 2.11. **Observational studies:** observational studies (cohort, case-control, cross-sectional) should be written according to the STROBE guideline. The STROBE checklist should be included in the presentation as a document.
- 2.12. **Clinical cases:** The clinical case presentation should follow the CARE guideline and be included in the Supplemental File for Review.
- 2.13. **DNA sequences and crystallographic structure determinations:** papers without a Genbank or Brookhaven number, respectively, will not be accepted in documents that include information on DNA sequences and crystallographic structure determination. Standardized gene nomenclature should be used throughout. Human genes' symbols and names can be found in the HUGO Gene Nomenclature Committee (HGNC) database.
- 2.14. **Conflict of interest and source of funding:** authors must declare the origin of any financial support received. A conflict of interest exists when the author (and/or co-authors) had or have economic or personal relationships that could have biased or inappropriately influenced their actions. In this case, it should be indicated when the relationship (direct or indirect) is related to the work that the authors describe in their manuscript. Potential sources of conflicts of interest may be: ownership of a patent or stock, being a member of the board of directors of a company related to the research, being a member of an advisory board or consulting committee of a company, and the receipt of fees from a company involved in the study. The existence of a conflict of interest does not prevent the publication of the article in the Journal. The corresponding author's responsibility is that all authors of the manuscript complete the conflict-of-interest form and include it at the time of submission of the document. The conflict-of-interest statement should be included in the "Acknowledgements" section.
- 2.15. **The appeal of decision:** in exceptional circumstances, authors may appeal the editorial decision by emailing the Editor ([contacto@ijidd.cl](mailto:contacto@ijidd.cl)) with a detailed explanation of why they are demanding the Editor's decision.

It is important to note that all revisions and resubmission of articles **must include** a letter of response, and the manuscript should highlight the changes made to assist the reviewers.

2.16. **Permissions:** Authors are responsible for obtaining permission to partially reproduce material (text, tables, or figures) from other publications. These permissions should be requested both from the author and from the publishing house that published the material and the institution that has financed the research and should be attached to the manuscript submission. Also, authors should include a statement that the article's content is original and has not been previously published or submitted or submitted for consideration to any other publication, either in whole or in part. Failure to disclose this information constitutes a serious breach of scientific ethics.

3. **MANUSCRIPT SUBMISSION:** Manuscripts should be submitted electronically through the online submission site <http://www.IJoID.cl/>. The use of an online submission and peer review site allows for immediate distribution of manuscripts and expedites the review process. It also allows authors to track the status of their manuscripts. Complete submission instructions are available on the site.

It is important to note that all revisions and resubmissions **must include** a response letter, and the manuscript should highlight the changes made as an aid to the reviewers.

3.1. **Manuscript files:** Manuscripts **must be uploaded** as a non-writing protected Word (.doc) file. The text file should contain the entire manuscript, including title page, abstract (English and Spanish), keywords (English and Spanish), clinical reference, main text, references, acknowledgments, statement of funding source and any possible conflict of interest, tables, and figure legends, but no embedded figures. In the text, any figure should be referred to as "figure 2", "Figure 2," and individual files should be uploaded with the same name. Figure files should be uploaded separately from the main text. While GIF, JPG, PICT, or bitmap files are acceptable for submission, only high-resolution TIF or EPS files are suitable for printing. Manuscripts should be formatted as described in the following guidelines. Ensure that all elements (figures and tables) are cited in the main text.

3.2. **Peer review:** Two or more peer reviewers will review all manuscripts submitted to IJOID in the field. Papers that do not conform to the general objectives of the Journal will be returned immediately without review. IJOID uses only blind review. The names of the reviewers will not be disclosed to the authors.

3.3. **Suggest a reviewer:** IJoID tries to keep the review process as short as possible to allow rapid publication of new scientific data. To facilitate this process, the author can suggest a potential international reviewer's name and email address. In addition to this option, the Editor will select one or two additional reviewers.

3.4. **Suspending the submission during the submission process:** You can stop a submission at any stage before clicking the "Submit" button and save it for later. The manuscript will be in "Unsubmitted Manuscripts," You can click on "Continue Submission" when you decide to continue.

3.5. **Submission confirmation email:** after submission, you will receive an email to confirm receipt of your manuscript. If you do not receive this email within 24 hours, please check your email address in the system. If the email address is correct, please contact [contacto@ijoid.cl](mailto:contacto@ijoid.cl).

Manuscript resubmission: If your manuscript was rejected, you might submit a modified version of your document. This should be submitted as a new manuscript, following the guidelines described in 3.2 above. Also, you should upload comments to the previous revision as "supplementary files for review."

3.6. **Manuscript resubmission:** if your manuscript was rejected, you might submit a modified version of your document. This should be submitted as a new manuscript, following the guidelines described in 3.2 above. Also, you should upload comments to the previous revision as "supplementary files for review."

4. **TYPES OF ACCEPTED MANUSCRIPTS:** IJoID publishes **original research articles, reviews** (systematic reviews, scoping, and umbrella reviews), **and clinical reports;** the Editor solicits narrative reviews. Any manuscript submitted for review is expected to represent unpublished material.

**Original research articles/systematic reviews** articles submitted to this section will deal with Periodontics, Prosthodontics, Implantology, Oral and Maxillofacial Surgery, Pediatric Dentistry, Implantology and Preprosthodontics, Oncology and Reconstructive Surgery, Aesthetics and Craniofacial Deformities, Craniomaxillofacial Traumatology, Temporomandibular Joint, Salivary Glands, among others. They may be research articles and experimental surgery or clinical trials.

**Clinical cases/clinical reports** may consist of the description of one or more clinical cases of particular interest and new surgical techniques or variants thereof, analysis of results obtained with a specific technique, or the treatment of a particular pathology.

**Letters to the Editor** will publish objections or comments related to previously published works or observations, or experiences written briefly. Those letters concerning articles previously published in the Journal will have the right to reply by the author, who may answer in a letter of similar length within one month. The Editorial Committee will evaluate the pertinence of the publication of the reply.

**Narrative Review** (bibliographic review) is requested exclusively by the Editor of the Journal on a particular topic of interest to the Journal. If you want to send a bibliographic review, you should send a letter to the Editor of the Journal to the email [contacto@IJoID.cl](mailto:contacto@IJoID.cl), indicating the review's pertinence and relevance. Once the Editor accepts the request, the review must be sent through the portal and conform to the publication rules specified for this section.

**Research protocols:** should report on planned or ongoing research studies.

5. **STRUCTURE AND FORMAT OF THE MANUSCRIPT:** it is essential to note that, before sending the manuscript to peers, it will be reviewed in terms of its format and structure; if it does not conform to the stipulations of these publication guidelines, the manuscript will be returned to the author, indicating what needs to be improved; if the modifications suggested by the Editorial Assistant are not made, the document will be rejected. To simplify the author's review of compliance with the publication guidelines, a checklist is attached at the end of these publication guidelines.

### 5.1 Format:

**Language:** The language of publication is Spanish; articles are also welcome in English.

**Abbreviations, symbols, and nomenclature:** only abbreviations standard in medicine and Dentistry should be used, and abbreviations in the title and abstract should be avoided. The first time an abbreviation appears, it should be preceded by the complete term to which it refers, except in standard units of measurement, expressed in International System Units. Chemical, physical, biological, and clinical units should always be strictly defined.

All manuscripts should be written in Arial font size 12, double spaced, letter size paper, and all pages should be numbered. In the case of original articles and systematic reviews, the maximum length will be 10 pages (not including abstract or bibliography); clinical cases, 6 pages; letters to the Editor, 2 pages. For other sections, please consult the email [contacto@IJoID.cl](mailto:contacto@IJoID.cl)

5.2 **Structure:** all articles submitted to IJOID must include:

The title page must consist of the title in Spanish and English of the manuscript and the names of the authors, their affiliation, and contact details of the corresponding author. (1 file in Word format).

- Conflict of interest and source of funding (1 file in Word format).
- Clinical relevance (1 file in Word format).
- Abstract and keywords: If the manuscript is written in Spanish, abstract and keywords in English should be attached; if the manuscript is written in English, abstract and keywords in Spanish should **NOT** be included.
- Introduction
- Materials and Methods
- Results
- Discussion
- References
- Tables (if applicable, one file for each table)
- Figure legends (if applicable)
- Figures (when applicable and uploaded as separate files)

\*The abstract, keywords, introduction, materials and methods, Discussion, and references should be in a single file in Word format.

**Title page:** should be concise and contain no more than 100 characters, including spaces. The title page should include a running title of no more than 40 characters; authors' first name and surname (or both surnames joined by a hyphen); full names of each author's institutions, **not including the academic or professional position or institution of higher education**, and the name, address, telephone number and email address of the



corresponding author. This page should be submitted in a separate file from the rest of the manuscript. (Example of title page: Juan Pérez (Juan Pérez-Soto).

University affiliation: Periodontology, Department of Conservative Dentistry, Faculty of Dentistry, University of Chile, Santiago, Chile.

Hospital/Health Service/Clinic Affiliation: Oral Rehabilitation, Dental Service, Hospital Salvador, Santiago, Chile.

Affiliation Private Practice: private practice)

Author of correspondence: Juan Pérez-Soto: Dept. of Conservative Dentistry, Faculty of Dentistry, University of Chile: Sergio Livingstone #943, Independencia, Santiago, Chile. 22222222. Juan.perez@odontologia.uchile.cl)

**Conflict of interest and source of funding:** authors are required to disclose all sources of institutional, private, and corporate financial support for their study. Providers of materials (free or discounted) should be named sources of funding and their location (city, country, and state) included. Authors should also disclose any potential conflicts of interest, such as patents, ownership, participation, consultancies, fees, and supply of materials by the manufacturer. Conflicts of interest and funding sources for the research will be published in a separate section entitled "Conflict of Interest and Funding Source Disclosure."

**Abstract:** should not contain abbreviations or references. The abstract should be organized according to the content of the paper.

The abstract should be organized with objectives, **materials and methods, results, and conclusions** for original research articles.

In clinical trials, it is recommended that the final abstract include the clinical trial registration number in a public database, such as [clinicaltrials.gov](http://www.clinicaltrials.gov).

The abstract should be submitted:

If the manuscript is in Spanish, it must include abstract in English; if the article is written in English, it must **NOT** involve abstract in Spanish.

At the end of the abstract in Spanish, a maximum of 6 keywords should be included according to those included in the Medical Subject Headings (MeSH) of Index Medicus/Medline available at <http://www.nlm.nih.gov/mesh/MBrowser.html>. In the case of manuscripts written in English, the keywords should be in English only.

Remember that, in the case of manuscripts written in Spanish, they should include an abstract in English; under this abstract in English, 6 keywords in English should also be included.

**Clinical relevance:** should not exceed 100 words and should not be a repetition of the abstract. It should provide a clear and concise explanation of the study's rationale, what was known before, and how the results advance knowledge in the field. IF necessary, it may also contain suggestions for clinical practice.

They should be structured with the following headings: **scientific rationale for the study, mains results, and practical implications.**



**Acknowledgments:** only those persons or entities were contributing significantly to making the work possible and whose inclusion as authors cannot be justified should be acknowledged; acknowledgments for technical assistance. Technical assistance should be recognized in a separate paragraph from the one devoted to acknowledging other acknowledgments.

All persons mentioned explicitly in Acknowledgements must be aware of and approve their inclusion in this section.

**5.3 Original research articles: articles** submitted to this section should deal with periodontics, prosthodontics, implantology, pediatric dentistry, oral surgery, implantology and prosthodontics, oncology and reconstructive surgery, orthognathic surgery, aesthetics and craniofacial deformities, craniomaxillofacial traumatology, temporomandibular joint, salivary glands, among others. The maximum word count is 3500 words, and a maximum of 7 elements (figures and tables) is allowed.

The original articles' main text should be organized with: Introduction; Materials and Methods; Results and Discussion; bibliographic references (maximum 25, see section 5.7).

**Abstract:** should contain a maximum of 200 words and 6 keywords.

**Introduction:** The work's objectives should be clearly mentioned, and the basis of the work should be summarized without extensive review of the subject and eliminating historical memories. Only those references that are strictly necessary should be cited.

**Material and method:** this section should specify the place, time, and population of the study. It should include necessary information about the design, describe the selection of the subjects studied, detailing the methods, apparatus, and procedures with enough details so that other researchers can reproduce the study. The type of statistical analysis used should be indicated, specifying the confidence interval. The studies should include the corresponding experiments or control groups; if not, the measures used to avoid biases should be explained, and their possible effect on the conclusions of the study should be commented on. If it is an original methodology, the reasons that led to its use should be explained, and its possible limitations should be described. Special mention should be made of the clinical follow-up of the patients or research animals, which should be sufficiently prolonged to evaluate the procedure tested. Names and initials of patients should not be used. The generic name(s) of the drug(s) used (avoiding trade names), as well as the dose administered and the route of administration, should be communicated. The ethical standards followed by investigators in both human and animal studies will be briefly described. Human studies must have the express approval of the local ethics and clinical trials committee, which must appear in the manuscript.

- (a) Evidence syntheses, including systematic and Umbrella Reviews, Mapping Reviews, Scoping Reviews and Structured Evidence Summaries** must be reported using the above guidelines.
- (b) Clinical trials** should be reported using CONSORT guidelines.
- (c) Statistical analysis** should provide sufficient detail as to the statistical analyses performed.

**(d) Human experimentation** will only be published if the research has been conducted following ethical principles, including the World Medical Association, Declaration of Helsinki (2008 version), and the site's additional requirements where the research was conducted. Additionally, it must be accompanied by a statement that the experiments were conducted with each subject's understanding and consent. It must also include a statement that the study has been reviewed and approved by an Ethics Committee.

When experimental animals are used, it should be clearly stated that appropriate measures were taken to minimize pain or discomfort. Experiments should be conducted under the guidelines established by the National Institute of Health (NIH) in the United States regarding the care and use of animals in experimental procedures or with the European Communities Council Directive of November 24, 1986 (86/609/EEC) and following local laws and regulations.

All human or animal studies should include an explicit statement in this section, identifying the Ethics Committee approval for each study. The Editor or reviewers reserve the right to reject manuscripts if they doubt the use of appropriate procedures.

**Results:** The results should be concise and clear and include the minimum necessary number of tables and figures. They should be presented so that there is no duplication and repetition of data in the text and the figures and tables.

**Discussion:** it can follow the following script: 1) conclusion based exclusively on the results. Any conclusion that does not follow the results obtained should be avoided. 2) importance, the relevance of the research conducted. 3) strengths. 4) limitations of the findings and 5) future perspective in the light of the results.

**5.4. Clinical cases/clinical reports:** may consist of the description of one or more clinical cases of particular interest, as well as new surgical techniques or variants thereof, analysis of results obtained with a specific technique or in the treatment of a particular pathology. The length shall not exceed 6 letter-size pages. The abstract and its translation should not exceed 150 words. The text should contain a maximum of 3000 words. The maximum number of signatory authors will be 6. 4 keywords in Spanish and English should be attached. The number of bibliographical references should not exceed 15 (see section 5.7). A maximum of 7 items (figures and/or tables) will be allowed.

The main text of the clinical reports should be organized with:

- Introduction
- Case report
- Discussion and conclusion
- References (see section 5.7-Vancouver)

**5.5. Letters to the Editor:** objections or comments related to previously published works or observations or experiences written in the brief form will be published. The maximum length of the text should not exceed 2 letter-size pages, and a maximum of 10 bibliographic citations will be allowed. Two items (figures and/or tables)

may be included. The number of signatories is limited to 4. Those letters that deal with articles previously published in the Journal will have the right to reply by the author, who may respond in a letter of similar length within one month. The Editorial Committee will evaluate the pertinence of the publication of the reply. The abstract and its translation shall be 250 words. Four keywords in Spanish and English should be attached, and the bibliography should not exceed 10 references.

**5.6. Narratives Reviews:** The Editor requests these from experts to comment on topics of general interest and scientific accuracy. They should have a maximum of 6 pages, without images or tables. The maximum number of citations allowed is 20.

The main manuscript of reviews should be organized as follows:

- Introduction
- Review of current literature
- Discussion and conclusion
- References (see section 5.8-Vancouver)

**5.7 Protocol:** Protocol manuscripts should report on planned or ongoing research studies; if data collection has been completed, the manuscript will not be considered, so it is suggested that protocol manuscripts be submitted at an early stage of the study. Protocols nearing completion of data collection will be treated on a case-by-case basis and the final decision on whether to consider a protocol for publication will rest with the Editor.

Investigators are requested to follow the SPIRIT (Standard Protocol Items for Randomized Trials) recommendations when writing their protocols and to include a completed SPIRIT checklist with the trial protocol submission.

PRISMA-P (Preferred reporting items for systematic review and meta-analysis protocols) is a new reporting guideline. An article outlining the checklist for the guideline has already been published. This checklist contains 17 essential and minimum components of a systematic review or meta-analysis protocol. Authors and evaluators of systematic reviews are encouraged to use PRISMA-P when writing and evaluating review protocols. Authors should include a completed PRISMA-P checklist with their protocol submission.

IJOID will consider publishing protocols for any study design, including observational studies and systematic reviews. Authors are encouraged to register research. Prospective registration is mandatory for any clinical trial. Acceptable registries for trials include [clinicaltrials.gov](http://clinicaltrials.gov). We recommend Prospero for registration of systematic reviews.

In addition to complying with formatting standards, editorial guidelines, licensing forms, and patient consent (when applicable to the study designs), protocols should include, at a minimum, the following elements:

- Manuscripts of protocols on planned or ongoing studies. Manuscripts reporting work already completed will not be considered protocols. The dates of the study should be included in the manuscript and in the cover letter.
- Protocols for studies requiring ethical approval, such as trials, will probably not be considered without authorization.
- Title: should include the specific type of study, e.g., randomized controlled trial.
- Abstract: should be structured with the following sections. Introduction; Methods and analysis; Ethics and dissemination. Registration data should be included as a final section, if applicable.
- Include a "Strengths and limitations" section after the abstract. This section should have no more than five bullet points related to the methods, not the results of the study. It will be published as an abstract box after the abstract in the final published article.
- Introduction: explain the rationale for the study and what evidence gap it can fill. Relevant previous literature, including relevant systematic reviews, should be cited.
- Methods and analysis: provide a full description of the study design, including the following. How the sample will be selected; the interventions to be measured; the sample size calculation (based on previous literature) with an estimate of how many participants will be needed for the primary outcome to be statistically, clinically and/or politically significant; what outcomes will be measured, when and how; a plan for data analysis.
- Ethics and dissemination: ethical and safety considerations should be included here, as well as any plans for dissemination (publications, data repository and preservation).
- Complete references.
- Authors' contributions: indicate how each author wrote the protocol.
- Funding statement: preferably worded as follows: "This work has been funded by [name of funder] under grant number [xxx]" or "This research has not received any specific grant from any funding agency in the public, commercial, or non-profit sectors."
- Conflict of Interest Statement.
- Word count: 4,000 words. If the word count exceeds this number, please indicate this in the cover letter.

5.8. **Bibliography (Vancouver):** only those citations that are considered essential and have been read by the authors should be included and, in a number, no more significant than the maximum corresponding to each section. The bibliography should be presented according to the order of appearance in the text with the corresponding correlative numbering. According to the "Uniform Requirements for Manuscripts Submitted for Publication in Biomedical Journals" prepared by the International, the article should always include the citation

number in superscript and parentheses Committee of Medical Journal Editors, available <http://www.icmje.org/>. Journal names should be abbreviated according to the style used in Index Medicus/Medline (See the "List of Indexed Journals," included each year in the January issue of Index Medicus/Medline(<http://www.nlm.nih.gov/mesh/MBrowser.html>))." See ICMJE recommendations at en (<http://www.icmje.org/recommendations/browse/manuscript-preparation/>). Textbooks and meeting proceedings should be avoided as far as possible. Phrases such as "unpublished observations" and "personal communication" should not be used as bibliographic citations. Footnote citations are not acceptable. Some examples of bibliographic citation formats are given below:

### Journals

**1 Original article.** All authors should be included when there are 6 or fewer; if there are more, cite the first 6 followed by "et al.":

Tarnow DP, Elian N, Fletcher P, Froum S, Magner A, Cho SC, et al. Vertical distance from the crest of bone to the height of the interproximal papilla between adjacent implants. *J Periodontol.* 2003;74:1785-8.

Tarnow DP, Cho SC, Wallace SS. The effect of inter-implant distance on the height of inter-implant bone Cresta. *J Periodontol.* 2000;71:546-9.

**2. Corporate author:**

Symptomatic multifocal osteonecrosis. A multicenter study. Collaborative Osteonecrosis Group. *Clin Orthop Relat Res.* 1999;(369):312-26.

**3. Journal volume supplement:**

Takagi M. Neutral proteinases and their inhibitors in the loosening of total hip prostheses. *Acta Orthop Scand.* 1996;67 Suppl 219: 29-33.

**4. Issue volume supplement :**

Glaser TA. Integrating clinical trial data into clinical practice. *Neurology.* 2002;58 12 Suppl 7:S6-12.

**5. Number without volume:**

Jané E. Sistemas de salud y desarrollo. *Quadern CAPS.* 1999;(28):7-16.

### **Books and other monographs**

**6. Author:**

Pauwels F. Atlas zur Biomechanik der gesunden und kranken Hüfte. Würzburg: Springer Verlag; 1973.

**7. Editor(s)/compiler(s) as author(s):**

Pérez de los Cobos J, Valderrama JC, Cervera G, Rubio G, editores. Tratado SET de trastornos adictivos. Madrid: Ed. Panamericana; 2006.

**8. Book chapter:**

Llanos-Cubas LF, Martín-Santos C. Anatomía funcional y biomecánica del raquis lumbar. En: Cáceres E, Sanmartí R, editor. Lumbalgia y lumbociatalgia. Tomo I. Barcelona: Masson SA; 1998. p. 1–21

#### **9. Published presentation**

Sanz-Aguado MA. La epidemiología y la estadística. En: Sánchez-Cantalejo E, editor. Libro de Ponencias del V Encuentro Marcelino Pascua; 16 junio 1995; Granada, España. Granada: Escuela Andaluza de Salud Pública; 1996. p. 35–44.

#### **10. Doctoral dissertations:**

García-Rueda FJ. Alteraciones del osteoclasto en la enfermedad de Paget [tesis doctoral], Salamanca, Universidad de Salamanca, 1987.

#### **11. Scientific or technical report:**

Dirección General para las Drogodependencias y Adicciones. Catálogo de los servicios asistenciales de los centros de tratamiento ambulatorio de Andalucía. Sevilla: Junta de Andalucía; 2003.

#### **12. Communication to Congress:**

Álvarez-Villas P, Cebamanos J, Escuder MC, Ribau MA, Ballester J. Osteonecrosis meseta tibial. Diagnóstico, diagnóstico diferencial y tratamiento. Actas del 33.º Congreso Nacional SECOT; octubre 1996. Alicante. SECOT; p. 202.

#### **13. Newspaper article:**

Sampedro J, Salvador I. Cientos de comercios de Castilla-La Mancha venden ilegalmente fármacos para el ganado. El País. 19 octubre 1999; p. 37 (col. 1-4).

#### **14. Legal material:**

Ley de Prevención de Riesgos Laborales. L. N.º 31/1995 (8 noviembre 1995).

#### **15. Electronic file:**

EPISAME Versión Macintosh [CD-ROM]. Madrid: Escuela Nacional de Sanidad, Universidad Nacional de Educación a Distancia; 1998.

#### **16. Web Page:**

Buscador de revistas médicas en Internet. Granada: Departamento de Histología, Universidad de Granada [actualizado 30 octubre 1998; citado 3 noviembre 1998]. Disponible en: <http://histolii.ugr.es/journals.html>

#### **17. Document on the Internet:**

Plan Nacional sobre Drogas. Encuesta domiciliaria 2005-2006. [consultado 06/06/2007]. Disponible en: <http://www.pnsd.msc.es/Categoria2/observa/pdf/Domiciliaria2005-2006.pdf>

#### **18. Journal article in electronic format:**

Berger A, Smith R. New technologies in medicine and medical journals. BMJ [edición electrónica]. 1999 [citado 14 enero 2000]; 319: [aprox. 1 pág.]. Disponible en: <http://www.bmj.com/cgi/content/full/319/7220/0>.

**19. Monograph article in electronic format:**

Badía X, Lizán L. Estudios de calidad de vida. En: Martín Zurro A, Cano Pérez JF, editores. Atención primaria. 5th ed (monografía en Internet): España: Elsevier; 2006 (citado 29 mayo 2006). Disponible en: <http://www.elsevier.es/librosvivos/martinzurro/indices.asp> 17.

**20. Audiovisual material:**

VIH+/SIDA: elementos de prevención [videocasete]. Cornellà de Llobregat: Aula de Formación; 1998.

**21. Unpublished material**

En prensa (en este caso los autores deben obtener confirmación de la futura publicación del trabajo citado): Sardi NA, Rapp E, Vakka LAO. Fish consumption and the risk of Alzheimer's disease. Eur J Nutr Neurol Sci. En prensa 2004.

**5.9. Tables, figures, and figure legends:**

- (a) Tables:** Units of measurement should be included in the column heading. They should be indicated correlatively in the text with Arabic numerals (for example, table 1). They should be double-spaced, without vertical resolutions, on separate pages and include: (a) table numbering with Arabic numerals; (b) corresponding statement-title; (c) at the bottom of each table, the abbreviations used shall be described in alphabetical order. An explanatory footnote should always accompany the abbreviations and abbreviations. If a table occupies more than one page, the headings should be repeated on the following page. The Journal will admit tables that occupy up to a maximum of one printed page of the Journal. They must complement, not duplicate, the text.
- (b) Figures:** they may be photographs or graphics and should be planned for 1 column width (8.0 cm), 1.5 column widths (13.0 cm), or 2 column widths (17.0 cm) and should be adequate for photocopy reproduction of the printed version of the manuscript. They should be uploaded separately from the text. They should be numbered consecutively in Arabic numerals (e.g., fig. 1). In case a figure is composed of more than one image (maximum 6 images), these will be identified in the text with the number and a lowercase letter (e.g., fig. 1a, fig. 1b). The letters in the figures should be in lowercase type, with the first letter capitalized. Units should have a single space between the number and the unit and follow SI nomenclature or the nomenclature common to a particular field. Thousands should be separated by a space (1 000). Unusual units or abbreviations should be spelled out in full or defined in the legend.

Figures should be in bmp, jpg, or tiff format, minimum 300 dots per inch (dpi), and minimum size of 8 cm. Word and MS PowerPoint graphics are not recommended for printed images. For scanned images, the scanning resolution to ensure good reproduction should be: lineart: >600 dpi; tones (including gel photographs): >300 dpi figures containing halftone and line images: >600 dpi.

Permissions: If all or parts of published illustrations are used, permission must be obtained from the copyright holder and the publisher who has published the material. It is the author's responsibility to obtain these in writing and provide copies to the publishers.



If photographs or patient data are reproduced, they should **not be subject-identifying**. In all cases, the authors must have obtained the **patient's informed consent/assent authorizing its publication, reproduction, and dissemination on paper and the Internet in IJOID**. Identification of the patients should be avoided. If this is not possible, written informed consent/assent must be obtained.

(c) Figure legends: should be a separate section of the manuscript and should begin with a brief title for the entire figure and continue with a short description of each image and symbols used; they should not contain any indication of methods. The font type should be Helvetica or Sans Serif, size 10. Histological reproductions should specify the staining used and the magnification.

5.10. **Supplementary material:** Supplementary material is considered to be the set of data or more figures or tables that will not be published in the printed edition of the Journal but will be visible in the online edition and should be uploaded as "Supporting information for online review and publication only."

6. **AFTER ACCEPTANCE:** After accepting a paper for publication, the manuscript will be sent to the Journal for production.

6.1. **Proof of corrections:** the author will receive an email alert containing a website link. The proof can be downloaded as a PDF file from this site (will require Acrobat Reader, can be downloaded free of charge from the site <http://www.adobe.com/products/acrobat/readstep2.html>). Proofs must be returned to the Editor within 3 days of receipt. Corrections are allowed only in typography; in the case of images, tables, and/or graphics, they may be modified only if the proofs are not clear.

6.2. **Publish before printing:** the articles, before their printed publication, in full text are published online, once the DOI (Digital Object Identifier), assigned by ScIELO Chile, has been obtained (for more information, see <http://www.doi.org/faq.html>).

The judgments and opinions expressed in articles and communications published in the International Journal of Interdisciplinary Dentistry are the sole responsibility or the thoughts of the author(s) and do not necessarily represent the Management Committee's opinion. Both the Management Committee and the publishing company disclaim any responsibility for such material. Neither the Management Committee nor the publishing company guarantees or endorses any product advertised in the Journal, nor does it guarantee the manufacturer's claims about such product or service. The editorial staff of the Journal shall have the authority to publish accepted articles on the date and in the order, it deems appropriate, depending on the subject matter and publication needs, and accepted papers may be published before and after others and vice versa.

**7. TRANSFER OF COPYRIGHT:** the author must read the declaration of authorship and assignment of copyright and must declare the existence or not of a conflict of interest in the text box created for this purpose. The text relating to copyright guarantees and assignment of copyright is reproduced below:

**7.1. Author's warranties and liability:** The author warrants that the texts, including any graphics, designs, or illustrations (from now on generically referred to as "the Papers") submitted to the International Journal of Interdisciplinary Dentistry for publication are original, unpublished and authored by him/her, and that they have not been previously published or simultaneously submitted to any other publisher for publication. If the work has been submitted to another entity or not an original article, the Editorial Committee reserves the right to publish the manuscript submitted, even if it has been approved for publication.

Likewise, the author guarantees, under his/her responsibility, that he/she holds all the exploitation rights over the Papers, that in no case do they infringe the rights of third parties, and that, if they involve the exploitation of third-party rights, the author has obtained the corresponding authorization to exploit them and to authorize their exploitation by ScholarOne and IJOID. Likewise, the author guarantees that the Works he/she does not violate personal data protection regulations. In particular, he/she ensures that he/she had obtained prior authorization and prior written consent from the patients or their relatives for their publication when such patients are identified in the Papers or when the information published makes them easily identifiable.

**7.2. Transfer of exploitation rights:** The author exclusively assigns to the Companies, with the right to transfer to third parties, all the exploitation rights derived from the works selected for publication in this or any other

ScholarOne publications and, in particular, those of reproduction, distribution, public communication (including interactive availability) and transformation (including adaptation, modification and, where appropriate, translation), for all forms of exploitation (including but not limited to: in paper, electronic, online, computer or audiovisual format, as well as in any other format, including for promotional or advertising purposes and/or for the creation of derivative products), for a worldwide territorial scope and the entire legal duration of the rights provided for in the current Consolidated Text of the Intellectual Property Law.

Consequently, the author may not publish or disseminate the papers selected for publication in the International Journal of Interdisciplinary Dentistry, either in whole or in part, nor authorize their publication to third parties without the express prior written permission International Journal of Interdisciplinary Dentistry. If it is found that the manuscript was published or is approved for publication in another journal, the Editorial Committee of the Journal reserves the right to apply sanctions to the author, such as the pick-up of the work where the author appears as such or co-author, or the prohibition of the author to publish in IJoID for a certain period.

During the manuscript submission, authors will be able to consult the full text of the conditions of the cession of rights at <http://www.IJOID.cl/>.

## **8. POLICY FOR HANDLING RETRACTIONS, WITHDRAWALS, AND EXPRESSIONS OF CONCERN**

### 8.1. Retractions

The journal is committed to maintaining the integrity of publications. It is committed to playing its part in preserving the integrity of the scholarly record, so it may occasionally be necessary to retract articles. For example, reports may be retracted if:

There is a significant scientific error that invalidates the conclusions of the article. (Misconduct or an honest mistake).

When the results have been previously published elsewhere without proper cross-referencing, permission, or justification.

When there are ethical problems such as plagiarism.

When unethical research has been reported.

### 8.2. Retraction Process

To ensure that retractions are handled following industry best practices and COPE ([Committee on Publication Ethics](#)) guidelines, the journal adopts the following retraction process:

An article requiring a potential retraction is brought to the journal editor's attention.

The journal editor must follow the step-by-step guidelines according to the COPE flowcharts (including evaluating a response from the article's author in question).

This step aims to ensure a consistent approach under industry best practices.

The final decision on retraction is communicated to the author and, if necessary, to any other relevant body, such as the author's institution, on occasion.

The retraction statement is posted online and published in the next available issue of the journal.

### 8.3. Complaint Procedure

To challenge a retraction or related matter, the procedure is as follows:

The complaint must be submitted through the Editor.

An independent investigation is then conducted. The analysis involves reviewing all correspondence relating to the case in question and, if necessary, obtaining further written responses to questions from the parties involved.

The objective of the investigation is to establish that correct procedures have been followed, decisions have been made based on academic criteria, that personal bias or prejudice of any kind has not influenced the outcome, and that appropriate sanctions have been applied where applicable.

The investigative panel will submit its findings to the Editor before communicating them to the appropriate parties.

Complainants may submit their complaint to the Committee on Publication Ethics (COPE).

### 8.4. Process for Issuing a Retraction Statement

When the decision is made to retract and the article to be retracted is the version of the record (i.e., it has been published in Early View or within an issue of a journal), a retraction statement will be issued and published separately. Still, it should be linked to the article being retracted. A "retracted" watermark will also be added; however, the article as first published will be retained online to maintain the scientific record.

#### **8.5. Circumstances in which an article may be removed.**

When an accepted article (representing an early version of an article) must be withdrawn because, for example, it contains errors, has been accidentally submitted twice, or violates some professional code of ethics, it may be removed.

Bibliographic information about the removed article should be retained for the scientific record, and an explanation, however brief, should be given about the circumstances of its removal.

### CHECK LIST IJoid

		RESEARCH WORK	STRUCTURED EVIDENCE SUMMARIES	CLINICAL CASE	LETTER TO EDITOR	NARRATIVE REVIEWS	PROTOCOL RESEARCH
Source	Arial 12	X	X	X	X	X	X
Space	Double	X	X	X	X	X	X
Paper Size	Letter	X	X	X	X	X	X
Numbered pages		X	X	X	X	X	X
Total pages		10	10	6	2	6	10
Title page structure		<p><b>All publications must have a title page with the following characteristics:</b>            100 characters            Running title: 40 characters  <u>Authors:</u> name and surname (e.g. Juan Pérez); name and two surnames separated by a hyphen (e.g. Juan Pérez-Pérez).  <u>Institutions:</u> University: Area/Department; Faculty; University; City; Country (Eg: Dept. of Pathology and Oral Medicine, Faculty of Dentistry, University of Chile, Santiago, Chile).            Office, hospital: Name of service; institution; City; Country (Ex: Periodontics Service, Hospital Salvador, Santiago, Chile).            Those who do not teach at universities should include: Private practice, City, Country. <u>Corresponding author contact information:</u> E-mail; telephone; mailing address.</p>					
Conflict of interest & Ethics Committee		<p>All publications must declare conflict of interest with the following text:            The authors declare that they have no conflict of interest. Once the article is accepted, you must send the conflict-of-interest form, signed by all the authors.            In addition, in case the manuscript involves human subjects, the certificate of the Ethics Committee authorizing the study or the publication in the case of Cases or Series of Clinical Cases must be included.</p>					
Source of funding		<p>All publications must declare if they have any source of financing: Project with competitive funds from your university, government and/or companies; in case of not having financing, it must also be indicated (This work does not have any financing).</p>					
Clinical significance		<p>All publications must have an additional file with the clinical relevance of the work with a maximum length of 100 words.</p>					
Summary of word count in Spanish/English		200 words	200 words	150 words	250 words		
Keyword in Spanish/English		6 words	6 words	4 words	4 words		
Introduction		X	X	X	X		

Methods	X	X	X	X		
Results	X	X	X	X		
Discussion	X	X	X	X		
References	25 *	35 *	15	10		20
Tables	Total: 7 (tables+fig)	Total: 10 (tables+fig)	Total: 7 (tables+fig)	Total: 2 (tables+fig)		NOT APPLICABLE
Figure legends	X	X	X	X		NOT APPLICABLE

\* In the case of Systematic Reviews with and without meta-analysis and Structured Evidence Summaries, a higher number of bibliographic references may be considered, depending on the number of included and excluded studies.

### FILES TO BE UPLOADED TO THE WEBSITE

	RESEARCH WORK	REVIEWS (SYSTEMATICS, UMBRELLA, MAPPING)	CLINICAL CASE	LETTER TO EDITOR	NARRATIVE REVIEWS	PROTOCOL RESEARCH
Title page	X	X	X	X	X	X
Conflict of interest	X	X	X	X	X	x
Funding source	X	X	X	X	X	X
Clinical significance	X	X	X	X	X	X
Tables	7	10	7	2	NOT APPLICABLE	
Figures						
Language certificate *						
Informed consent/assent	X	NOT APPLICABLE	X	X	X	X
Approval of the Ethics Committee	X	NOT APPLICABLE	X	X	X	X

\* In case the article is in English, a certificate must be attached, considering that the official language of the journal is Spanish.